1. FV 47 Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Issue 8 (August 2019) Authors: Hauser, S.; Hartung, H.P.; Kappos, L.; Montalban, X.; Hughes, R.; Koendgen, H.; McNamara, J.; Pradhan, A.; Wormser, D.; Wolinsky, J.S. Journal: Clinical neurophysiology Issue: Volume 130:Issue 8(2019:Aug.) Page Start: e142 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. P36 Serum immunoglobulin levels and risk of serious infections in the pivotal phase III trials of ocrelizumab in multiple sclerosis and their open-label extensions. Issue 4 (April 2020) Authors: Derfuss, T.; Weber, M.; Hughes, R.; Eggebrecht, J.; Wang, Q.; Sauter, A.; Koendgen, H.; Hauser, S.; Bar-Or, A.; Hartung, H.P. Journal: Clinical neurophysiology Issue: Volume 131:Issue 4(2020:Apr.) Page Start: e196 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗